Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours
暂无分享,去创建一个
C. Scrideli | L. Tone | J. A. Yunes | S. Brandalise | A. Moreira | M. Castro | A. Latronico | C. Martinelli | S. Tucci | L. Colli | A. Seidinger | M. J. Mastellaro | L. Mermejo | M. C. Fragoso | S. Antonini | L. Ramalho | L. F. Leal | A. L. Seidinger
[1] E. Lalli,et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Saggioro,et al. Components of the Canonical and Non-Canonical Wnt Pathways Are Not Mis-Expressed in Pituitary Tumors , 2013, PloS one.
[3] R. Kuick,et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. , 2012, The American journal of pathology.
[4] Hans Clevers,et al. Wnt/β-Catenin and MAPK Signaling: Allies and Enemies in Different Battlefields , 2012, Science Signaling.
[5] G. Hammer,et al. Adrenocortical stem and progenitor cells: Implications for adrenocortical carcinoma , 2012, Molecular and Cellular Endocrinology.
[6] A. Latronico,et al. Insulin-like growth factor system on adrenocortical tumorigenesis , 2012, Molecular and Cellular Endocrinology.
[7] J. Bertherat,et al. Wnt/β-catenin signalling in adrenal physiology and tumour development , 2012, Molecular and Cellular Endocrinology.
[8] M. Fassnacht,et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.
[9] A. Kikuchi,et al. Wnt5a: its signalling, functions and implication in diseases , 2012, Acta physiologica.
[10] L. Ramalho,et al. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors. , 2011, The Journal of clinical endocrinology and metabolism.
[11] T. L. Mazzuco,et al. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. , 2011, The Journal of clinical endocrinology and metabolism.
[12] Martin Fassnacht,et al. Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.
[13] T. Giordano. Classification of adrenal cortical tumors: promise of the 'molecular' approach. , 2010, Best practice & research. Clinical endocrinology & metabolism.
[14] J. Bertherat,et al. β-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma , 2010, Clinical Cancer Research.
[15] J. Bertherat,et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. , 2010, Cancer research.
[16] Yingqun Wang,et al. Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy , 2009, Molecular Cancer Therapeutics.
[17] J. Scheys,et al. In search of adrenocortical stem and progenitor cells. , 2009, Endocrine reviews.
[18] J. Jessen. Noncanonical Wnt signaling in tumor progression and metastasis. , 2009, Zebrafish.
[19] F. Beuschlein,et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.
[20] Hideki Yamamoto,et al. Tumor formation due to abnormalities in the β‐catenin‐independent pathway of Wnt signaling , 2008, Cancer Science.
[21] I. Bourdeau,et al. Frequent mutations of β‐catenin gene in sporadic secreting adrenocortical adenomas * , 2007, Clinical endocrinology.
[22] G. Turashvili,et al. Wnt Signaling Pathway in Mammary Gland Development and Carcinogenesis , 2007, Pathobiology.
[23] I. Ng,et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. , 2006, Gastroenterology.
[24] R. Nusse,et al. Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.
[25] Jeffery R Barrow,et al. Wnt/PCP signaling: a veritable polar star in establishing patterns of polarity in embryonic tissues. , 2006, Seminars in cell & developmental biology.
[26] M. Katoh,et al. WNT/PCP signaling pathway and human cancer (review). , 2005, Oncology reports.
[27] T. Andersson,et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. , 2005, Cancer research.
[28] M. de Castro,et al. Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[29] G. Brabant,et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma , 2005, Oncogene.
[30] E. Pinto,et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. , 2004, Arquivos brasileiros de endocrinologia e metabologia.
[31] M. Bittner,et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.
[32] E. Pinto,et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. , 2001, The Journal of clinical endocrinology and metabolism.
[33] B. Figueiredo,et al. [Childhood adrenocortical tumors]. , 1997, Arquivos brasileiros de endocrinologia e metabologia.
[34] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[35] D. Schteingart. Transcriptome Analysis Reveals that p53 and β-Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers , 2011 .
[36] W. Mcdougal. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.